SHSE:688221 (China)
Â
Class A
Â¥
8.57
+0.16 (+1.9%)
Apr 11
What is a stock summary page? Click here for an overview.
Business Description
Frontier Biotechnologies Inc
ISIN : CNE100005XF5
Share Class Description:
SHSE:688221: Class ACompare
Compare
Traded in other countries / regions
688221.China Index Membership
SSE Composite Index IPO Date
2020-10-28Description
Frontier Biotechnologies Inc is an innovative biomedical company. It is engaged in the production and sales of innovative drugs for major unmet clinical needs. The company focuses on the research and development of new drugs in the field of long-acting peptides and differentiated product development strategies for unmet clinical and patient needs.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.48 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.39 | |||||
| Debt-to-EBITDA | -1.66 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.79 | |||||
| Beneish M-Score | -3.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.6 | |||||
| 3-Year EBITDA Growth Rate | -2.7 | |||||
| 3-Year EPS without NRI Growth Rate | -4.2 | |||||
| 3-Year FCF Growth Rate | 5 | |||||
| 3-Year Book Growth Rate | -15.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 29.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 18.55 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.91 | |||||
| 9-Day RSI | 41.26 | |||||
| 14-Day RSI | 40.6 | |||||
| 3-1 Month Momentum % | 8.23 | |||||
| 6-1 Month Momentum % | 70.4 | |||||
| 12-1 Month Momentum % | 45.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.14 | |||||
| Quick Ratio | 2.02 | |||||
| Cash Ratio | 1.39 | |||||
| Days Inventory | 249.52 | |||||
| Days Sales Outstanding | 136.46 | |||||
| Days Payable | 91.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | -2.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.04 | |||||
| Operating Margin % | -178.23 | |||||
| Net Margin % | -209.43 | |||||
| FCF Margin % | -186.38 | |||||
| ROE % | -21.9 | |||||
| ROA % | -13.35 | |||||
| ROIC % | -17.66 | |||||
| 3-Year ROIIC % | -14.41 | |||||
| ROC (Joel Greenblatt) % | -29.19 | |||||
| ROCE % | -15.87 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.94 | |||||
| PB Ratio | 2.79 | |||||
| Price-to-Tangible-Book | 3.3 | |||||
| EV-to-EBIT | -10.89 | |||||
| EV-to-EBITDA | -10.89 | |||||
| EV-to-Revenue | 21.97 | |||||
| EV-to-FCF | -11.12 | |||||
| Price-to-GF-Value | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 19.48 | |||||
| Earnings Yield (Greenblatt) % | -9.18 | |||||
| FCF Yield % | -7.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Frontier Biotechnologies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 133.675 | ||
| EPS (TTM) (Â¥) | -0.75 | ||
| Beta | 1.59 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.36 | ||
| Volatility % | 39.21 | ||
| 14-Day RSI | 40.6 | ||
| 14-Day ATR (Â¥) | 0.488049 | ||
| 20-Day SMA (Â¥) | 9.194 | ||
| 12-1 Month Momentum % | 45.22 | ||
| 52-Week Range (Â¥) | 4.48 - 10.71 | ||
| Shares Outstanding (Mil) | 374.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Frontier Biotechnologies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Frontier Biotechnologies Inc Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Frontier Biotechnologies Inc Frequently Asked Questions
What is Frontier Biotechnologies Inc(SHSE:688221)'s stock price today?
The current price of SHSE:688221 is ¥8.57. The 52 week high of SHSE:688221 is ¥10.71 and 52 week low is ¥4.48.
When is next earnings date of Frontier Biotechnologies Inc(SHSE:688221)?
The next earnings date of Frontier Biotechnologies Inc(SHSE:688221) is .
Does Frontier Biotechnologies Inc(SHSE:688221) pay dividends? If so, how much?
Frontier Biotechnologies Inc(SHSE:688221) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers